Marshall Richard Henry 4

What Happened Marshall Richard Henry, Chief Medical Officer of TriSalus Life Sciences (TLSI), received equity awards on June 29, 2026: 60,000 restricted stock units (RSUs) and 120,000 derivative awards (reported as a grant at $0.00). The filing shows acquisition values of $0 for both items because no cash was paid at grant. These are awards, not open‑market purchases or sales.

Key Details

• Transaction date: 2026-06-29; reported on Form 4 filed the same day.
• Awards: 60,000 RSUs (payable in common stock) and 120,000 derivative awards (option-style grant) at $0.00.
• Vesting for RSUs (F1): vests in four equal annual installments beginning June 29, 2027, subject to continued service.
• Vesting for derivative award (F2): 1/4 vests on June 29, 2027 (one‑year anniversary), then 1/36th of the remainder vests monthly thereafter, subject to continued service.
• Shares owned after the transaction: not reported in the provided summary of the Form 4.
• Filing timeliness: filed the same day as the transaction (no late filing indicated in this record).

Context RSUs convert to actual shares only as they vest and are typically seen as a retention incentive; the derivative award follows an option‑style vesting schedule and will require vesting (and possibly exercise) before resulting in shares. Because these are grants (not purchases or sales), they reflect compensation/retention actions rather than an immediate market‑signal buy or sell.